Semaglutide: The Weight-Loss Drug That Protects the Heart

Semaglutide earned its heart-protection result in people who already had cardiovascular disease. Researchers followed them for more than three years on average, counting heart attacks, strokes and cardiovascular deaths. The group assigned semaglutide had fewer of those events. SELECT, 2023

That is a much bigger ambition for a weight-loss drug than fitting into smaller jeans.

The interesting part is how you get from wanting less lunch to protecting a heart. To follow that story, start with an experiment where the researchers measured lunch.

Day 2 of 30 Peptides in 30 Days.

In a 2021 trial, researchers assigned 72 adults with obesity to semaglutide or placebo for 20 weeks. At the end, they served a lunch where participants could eat until they felt comfortably full.

The semaglutide group consumed 35% fewer calories than the placebo group at that meal. Participants also reported less hunger, fewer cravings and better control over eating. That 35% describes the test lunch, not every meal for the rest of their lives. Friedrichsen et al., 2021

Think about the practical difference between leaving food on a plate because you are full and leaving it there while mentally negotiating your way through the rest of the afternoon. Both can produce a smaller lunch. One asks a lot less of you.

Semaglutide acts on the receptor for GLP-1, a hormone involved in blood-sugar regulation and appetite. A receptor is the receiving end of a chemical message. Activating this one changes signals involved in hunger and fullness.

The engineering is clever, too. Researchers designed semaglutide to resist enzymatic breakdown and bind strongly to albumin, a protein in blood. Those changes keep it around long enough for once-weekly dosing. They took a biological signal and made a durable medicine from it. Lau et al., 2015

The lunch experiment makes the mechanism tangible. The next question is whether that difference keeps adding up after people go home.

STEP 1 enrolled 1,961 adults with obesity, or overweight plus a weight-related condition, without diabetes. Participants received weekly semaglutide injections, targeting 2.4 mg, or placebo for 68 weeks. Both groups received support for diet and physical activity.

Average weight loss reached 14.9% with semaglutide, compared with 2.4% with placebo. Wilding et al., 2021

For a person starting at 220 pounds, those percentages translate to about 33 pounds versus 5 pounds. That is an illustration of the group averages, not a forecast for a particular person.

The comparison matters. Researchers gave both groups lifestyle help. The drug added a substantial effect on top of that support.

It also changes how I would frame the usual conversation about effort. A treatment that makes eating less easier has practical value. Difficulty is a cost of a weight-loss strategy, not a feature you need to preserve.

But a bathroom scale cannot tell you whether somebody will have a heart attack. Proving that requires a different experiment, and a much longer wait.

SELECT randomly assigned 17,604 adults aged 45 or older, with established cardiovascular disease and a body mass index (BMI) of at least 27, to semaglutide or placebo. They had no diabetes. Treatment was added to usual cardiovascular care; the target was a weekly 2.4 mg injection.

Over an average 39.8 months, the combined endpoint of cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.5% versus 8.0% of participants. The time-to-event analysis found a 20% relative reduction. Lincoff et al., 2023

Put the absolute result beside the headline. Roughly 65 out of every 1,000 people assigned semaglutide experienced one of those outcomes, compared with 80 out of every 1,000 assigned placebo. About 15 fewer per 1,000 over the trial's follow-up, using the rounded percentages.

That is what heart protection meant here. In March 2024, the FDA approved Wegovy injections to reduce these risks in adults with cardiovascular disease and overweight or obesity. FDA announcement

If your entire picture of semaglutide is a before-and-after photo, this is the result that picture cannot show. A photo can document a smaller waist. It cannot show a future hospital admission that treatment helps someone avoid.

The trial establishes the benefit of the treatment strategy. It does not separate exactly how much came from losing weight versus other effects of the drug. Weight loss and changes in cardiovascular biology happened together. SELECT discussion

For someone already living with cardiovascular disease, that distinction does not erase the result. It makes the research question more interesting: which effects should future treatments aim to strengthen?

A medicine has to fit into a person's life for years if the goal is long-term health. Tolerability is part of whether that happens. In SELECT, adverse events led 16.6% of the semaglutide group to stop treatment, compared with 8.2% on placebo. Gastrointestinal problems drove much of the difference. Ryan et al., 2024

Then there is the question of what happens after stopping.

The STEP 1 extension followed 327 participants after the trial's medication and structured lifestyle intervention ended. Over the following year, the semaglutide group regained about two-thirds of its previous weight loss, on average. The group was still below its starting weight, but much of the change had reversed. Wilding et al., 2022

That makes maintenance a question to ask at the beginning. If the plan is to use a treatment briefly, reach a target and stop, what is supposed to sustain the result afterward?

There is encouraging evidence on the other side of that question. SELECT's longer follow-up found an average weight reduction of 10.2% at four years in the semaglutide group, versus 1.5% with placebo. That analysis included participants who discontinued treatment. Ryan et al., 2024

These are different populations and different studies, so the numbers are not a head-to-head comparison. Together, they make a useful planning point: a durable result deserves a durable plan.

If you are considering semaglutide, start by naming the problem you want treatment to solve. Is appetite making weight management difficult? Are you managing obesity alongside established cardiovascular disease? Those goals give the conversation more direction than asking for the biggest percentage on a weight-loss chart.

Then agree with your clinician on what you will follow alongside weight. That might include waist size, blood pressure, blood sugar when relevant, and whether eating and daily life feel manageable. Those measurements help assess your response; none can tell an individual that they personally avoided a heart attack.

Finally, discuss maintenance, tolerability and access before you reach the target. A plan that works only until the next refill problem needs more work.

Semaglutide gives us a concrete reason to expect more from obesity treatment. For people with established cardiovascular disease and excess weight, preventing another major event belongs in the conversation from the start.

Next in the series is GHK-Cu, the copper peptide that helps tell skin to rebuild.

Interested in metabolic health, recovery or skin? The Peptide Map organizes compounds by goal and puts the results behind them in one place, so you can build a useful shortlist.

Get the Peptide Map

For entertainment and education only. Not medical advice. Talk to your doctor before starting anything.